Matches in Nanopublications for { ?s ?p "[Although the frequency of mutations in the p16/CDKN2 gene has been detected in approximately 30% of non-small cell lung cancer, loss of heterozygosity on 9p has been observed in greater than 70% of non-small cell lung cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- NP540055.RAXnJzBK_Vj9UWJNsYCQhSUcbMfymGK2clQhMRbtfs6FQ130_assertion description "[Although the frequency of mutations in the p16/CDKN2 gene has been detected in approximately 30% of non-small cell lung cancer, loss of heterozygosity on 9p has been observed in greater than 70% of non-small cell lung cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP540055.RAXnJzBK_Vj9UWJNsYCQhSUcbMfymGK2clQhMRbtfs6FQ130_provenance.
- NP759748.RAccQZsK2HXuzW8lZtHj7Jn8Ty8Dq-iIxVcaGwPAurcn8130_assertion description "[Although the frequency of mutations in the p16/CDKN2 gene has been detected in approximately 30% of non-small cell lung cancer, loss of heterozygosity on 9p has been observed in greater than 70% of non-small cell lung cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP759748.RAccQZsK2HXuzW8lZtHj7Jn8Ty8Dq-iIxVcaGwPAurcn8130_provenance.
- assertion description "[Although the frequency of mutations in the p16/CDKN2 gene has been detected in approximately 30% of non-small cell lung cancer, loss of heterozygosity on 9p has been observed in greater than 70% of non-small cell lung cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Although the frequency of mutations in the p16/CDKN2 gene has been detected in approximately 30% of non-small cell lung cancer, loss of heterozygosity on 9p has been observed in greater than 70% of non-small cell lung cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Although the frequency of mutations in the p16/CDKN2 gene has been detected in approximately 30% of non-small cell lung cancer, loss of heterozygosity on 9p has been observed in greater than 70% of non-small cell lung cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Although the frequency of mutations in the p16/CDKN2 gene has been detected in approximately 30% of non-small cell lung cancer, loss of heterozygosity on 9p has been observed in greater than 70% of non-small cell lung cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP300885.RAYIxQIR-K0D6lh-2_fvXgztwT09ONbCogCaYRMwlAk5c130_assertion description "[Although the frequency of mutations in the p16/CDKN2 gene has been detected in approximately 30% of non-small cell lung cancer, loss of heterozygosity on 9p has been observed in greater than 70% of non-small cell lung cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP300885.RAYIxQIR-K0D6lh-2_fvXgztwT09ONbCogCaYRMwlAk5c130_provenance.
- NP1365273.RAaBux0YU6gnzAMvfvDkEiqlVfggnNE4PVUVcfoYBtWp8130_assertion description "[Although the frequency of mutations in the p16/CDKN2 gene has been detected in approximately 30% of non-small cell lung cancer, loss of heterozygosity on 9p has been observed in greater than 70% of non-small cell lung cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1365273.RAaBux0YU6gnzAMvfvDkEiqlVfggnNE4PVUVcfoYBtWp8130_provenance.
- NP300675.RAr4GRO5i1k4K2x2JX52kV-LBxR1hp77TUT6DgWf1_K9g130_assertion description "[Although the frequency of mutations in the p16/CDKN2 gene has been detected in approximately 30% of non-small cell lung cancer, loss of heterozygosity on 9p has been observed in greater than 70% of non-small cell lung cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP300675.RAr4GRO5i1k4K2x2JX52kV-LBxR1hp77TUT6DgWf1_K9g130_provenance.
- NP1365270.RAmWOY9TxBfDYeU3UQ2cEIprMxQXLTYF9Fwpfrw4QVWF4130_assertion description "[Although the frequency of mutations in the p16/CDKN2 gene has been detected in approximately 30% of non-small cell lung cancer, loss of heterozygosity on 9p has been observed in greater than 70% of non-small cell lung cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1365270.RAmWOY9TxBfDYeU3UQ2cEIprMxQXLTYF9Fwpfrw4QVWF4130_provenance.
- NP1365272.RAgd44uihW04aR-njshsw6Ne2af0aTd026mRuU86qrB_M130_assertion description "[Although the frequency of mutations in the p16/CDKN2 gene has been detected in approximately 30% of non-small cell lung cancer, loss of heterozygosity on 9p has been observed in greater than 70% of non-small cell lung cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1365272.RAgd44uihW04aR-njshsw6Ne2af0aTd026mRuU86qrB_M130_provenance.
- NP1365274.RAKu4A4kwCzrE7bp8P9oaQsXDrASIgL_wm00nNhW5Zd64130_assertion description "[Although the frequency of mutations in the p16/CDKN2 gene has been detected in approximately 30% of non-small cell lung cancer, loss of heterozygosity on 9p has been observed in greater than 70% of non-small cell lung cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1365274.RAKu4A4kwCzrE7bp8P9oaQsXDrASIgL_wm00nNhW5Zd64130_provenance.